George Miller, MD
Cardiovascular Disease · Sugar Land, TXNPI 1760443790
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $167,486 of the $167,586 with a category attached, or 99.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 85.4% of it on its own, with 2 other manufacturers making up the rest. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $2094.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$143K
- Shire North American Group Inc$24K
- Pfizer$30
What the payments were for
- Consulting fees$167,486100%
- Travel & lodging$700%
- Food & beverage$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $143,137 |
| Shire North American Group Inc | 12 | $24,420 |
| Pfizer | 1 | $30 |
How this compares
$167,586 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $7,279 |
| Potassium Chloride | 13 | $223 |
| Lisinopril | 15 | $89 |
| Furosemide | 16 | $87 |
| Methylprednisolone | 11 | $71 |
| Dexamethasone | 19 | $62 |
| Alprazolam | 14 | $44 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Sugar Land
- Byron EllisSugar Land$118K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.